Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

ABSTRACT:

Background

In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.

Objective

To delineate the role of lanreotide in the treatment of acromegaly.

Methods

Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.

Results

Treatment with lanreotide slow release and lanreotide Autogel((R)) normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel((R)) on GH and IGF-I levels was comparable w

SUBMITTER: Roelfsema F 

PROVIDER: S-EPMC2721386 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature